Compare EPAM Systems Inc (EPAM) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs Cassava Sciences Inc — how do they compare? EPAM Systems Inc trades at $113.24 (market cap $5.87B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: EPAM Systems Inc is far larger — about 149× Cassava Sciences Inc's market cap, and EPAM Systems Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EPAM Systems Inc for 37 Days and Cassava Sciences Inc for 37 Days on average.
| EPAM | FLNA | |
|---|---|---|
Market Cap | $5.87B | $39.40M |
Volume | 847,420 | 759,018 |
Sector | Technology | Health |
52-Week High | $221.40 | $4.64 |
52-Week Low | $76.04 | $0.68 |
Typical Hold Time | 37 Days | 37 Days |
Enterprise Value | $5.24B | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $113.86, up 5.11% today, with strong technical momentum as the stock approaches resistance near $115. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.46B in 2025, though net margins compressed to 6.92%. Recent news highlights EPAM's cloud infrastructure achievements and activist investor pressure for share buybacks.
The outlook remains cautiously optimistic with a consensus price target of $119 offering 4.5% upside. Key risks include North American growth slowdown and AI disruption to legacy services. Analyst sentiment is predominantly bullish (59% Buy ratings), but investors should monitor Q3 earnings and management's response to shareholder value concerns.
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
